Curis


Curis is a clinical-stage biotechnology company developing orally administered small-molecule therapeutics and immune-modulatory agents for oncology. The company conducts early-phase (Phase 1/2) trials, including dose-escalation and expansion cohorts, across hematologic malignancies and selected solid tumors. Clinical programs integrate translational biomarker and PK/PD assessments and run as multicenter studies in the United States and multiple international locations.

Industries

Biotechnology
Health Care
Medical
Biotechnology Research

Nr. of Employees

small (1-50)

Curis

Lexington, Massachusetts, United States


Patents

Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

US-12403142-B2

View Details

Crystal forms of immunomodulators

US-12252475-B2

View Details

Combination therapies for the treatment of cancer

US-12178821-B2

View Details

Conjoint therapies for immunomodulation

US-12064418-B2

View Details

Crystal forms of immunomodulators

US-11939306-B2

View Details

Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

US-11654136-B2

View Details
View All Patents

Products

Clinical‑stage oral IRAK4/FLT3‑targeting kinase inhibitor (hematologic malignancies and selected solid tumors)

A clinical‑stage orally administered small‑molecule kinase inhibitor being developed for IRAK4‑driven hematologic malignancies and other cancers; evaluated in multiple Phase 1/2 studies including monotherapy and combination regimens.

Clinical‑stage HDAC/PI3K inhibitor program (MYC‑altered cancers)

A clinical‑stage program combining HDAC and PI3K inhibitory activity being developed for MYC‑altered cancers and evaluated in early‑phase studies.

Clinical‑stage immune‑modulatory programs (PD‑1/PD‑L1 and other checkpoint pathways)

Early‑stage immune checkpoint and immune‑modulatory programs targeting PD‑1/PD‑L1 and other checkpoint pathways being evaluated in proof‑of‑principle or early clinical activity studies.

Emavusertib

An IRAK4 inhibitor targeted therapy being developed for IRAK4-driven leukemia (AML/MDS) and lymphoma (NHL, CLL, WM).

AU-2807

An IRAK-4 small molecule inhibitor profiled for kinase inhibition, in-vivo efficacy in a rat CIA model, and pharmacokinetics.

AU-6686

An IRAK-4 small molecule inhibitor demonstrating potent target engagement and inhibition of IRAK-1 phosphorylation.

View All Products

Expertise Areas

  • Clinical trial management
  • Phase 1/2 oncology development
  • Oncology small‑molecule drug development
  • Combination therapy development (targeted + chemo/immunotherapy)
  • Show More (5)

Key Technologies

  • Oral small‑molecule kinase inhibitors (IRAK4, FLT3)
  • Model‑assisted dose‑escalation methods (e.g., BOIN)
  • Pharmacokinetic and pharmacodynamic assays
  • Tumor biopsy–based translational assays
  • Show More (4)

News & Updates

Press release announcing the pricing of a public offering.

Press release reporting dosing of the first five patients in a CLL clinical study.

Press release summarizing a positive update for the company's IRAK4‑targeting clinical program.

Corporate presentation and investor slide deck.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.